Old Articles: <Older 7921-7930 Newer> |
|
The Motley Fool October 5, 2011 Arlene Weintraub |
Merck Fine-Tunes Biosimilars Strategy as FDA Guidelines Loom Merck readies itself to enter this potential new market. |
The Motley Fool October 5, 2011 Dan Caplinger |
Has Teva Pharmaceutical Become the Perfect Stock? Teva still looks poised to stay near perfection for the indefinite future. |
The Motley Fool October 3, 2011 Brian Orelli |
About That Developing Technology... Sangamo's diabetic neuropathy drug, SB-509, fails to impress. |
The Motley Fool October 3, 2011 Brian D. Pacampara |
Emergent BioSolutions Shares Jumped: What You Need to Know Shares of biodefense specialist Emergent BioSolutions popped 13% on Monday after landing a contract with the U.S. government to supply it with 44.75 million doses of anthrax vaccine BioThrax. |
The Motley Fool October 3, 2011 Brian D. Pacampara |
Pharmaceutical Product Development Shares Soared: What You Need to Know Shares of Pharmaceutical Product Development skyrocketed 25% Monday after The Carlyle Group and Hellman & Friedman LP agreed to buy the health-care research specialist for $3.8 billion. |
Chemistry World October 2011 Bibiana Campos Seijo |
Editorial: Odd Couple McLaren's expertise in building Formula One cars is to be put to use in the manufacture of antibiotics, vaccines and Lucozade in an unlikely alliance between the motor racing team and GlaxoSmithKline. |
CRM October 2011 Paul Hyman |
Tracking Medical Treatments in Real Time IBM Business Analytics is not only empowering physicians to rate their performance but also teaching them how to improve it |
CRM October 2011 Brittany Farb |
The Doctor Gets a Social Prescription YouBeauty enlists Extole to launch a social media campaign |
IEEE Spectrum October 2011 Joseph M. Smith |
Wireless Health Care Wireless technologies are about to transform health care, and not a moment too soon |
The Motley Fool September 30, 2011 David Williamson |
This Week in Health Care Pharma news about Pfizer, AstraZeneca, and the multibillion-dollar battle to replace the maligned blood-thinner warfarin. |
<Older 7921-7930 Newer> Return to current articles. |